Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Cadonilimab + Capecitabine + Oxaliplatin |
| Indication/Tumor Type | gastroesophageal junction adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | gastroesophageal junction adenocarcinoma | predicted - sensitive | Cadonilimab + Capecitabine + Oxaliplatin | Phase III | Actionable | In a Phase III trial (COMPASSION-15), first-line combination therapy with Cadonilimab, Xeloda (capecitabine), and Eloxatin (oxaliplatin) demonstrated safety in CD274 (PD-L1)-positive (CPS >=5), ERBB2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma patients, and resulted in an improved median overall survival (15.3 vs 10.9 mo, HR=0.58) and median progression-free survival (6.9 vs 5.5 mo, HR=0.51) compared to placebo plus chemotherapy (PMID: 39843940; NCT05008783). | 39843940 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39843940) | First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. | Full reference... |